secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001140361-23-030566
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis pilots Aquadex with DaVita; issues 1.3M-share warrant to DaVita
------------------------------------------------------------------------

- Supply and Collaboration Agreement with DaVita to pilot Aquadex ultrafiltration therapy for heart failure in select U.S. markets; pilot expected Q3 2023 through May 2024.
- DaVita receives warrant for 1,289,081 shares at $3.2996/share, vesting in four tranches tied to milestones including pilot extension and revenue achievements.
- DaVita has option to extend agreement for up to 10 years post-pilot; granted registration rights and participation rights in future financings.
- Nuwellis CEO cites DaVita’s clinical infrastructure to accelerate adoption of ultrafiltration therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/0001140361-23-030566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/brhc20054628_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-030566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer